European Radiology

, Volume 26, Issue 6, pp 1696–1704 | Cite as

The value of a rapid contrast-enhanced angio-MRI protocol in the detection of head and neck paragangliomas in SDHx mutations carriers: a retrospective study on behalf of the PGL.EVA investigators*

  • Guillaume Gravel
  • Patricia Niccoli
  • Vincent Rohmer
  • Guy Moulin
  • Françoise Borson-Chazot
  • Pascal Rousset
  • Anne Pasco-Papon
  • Claude Marcus
  • Frédérique Dubrulle
  • Hervé Gouya
  • François Bidault
  • Benoit Dupas
  • Jean Gabrillargues
  • Aurore Caumont-Prim
  • Anne Hernigou
  • Anne-Paule Gimenez-Roqueplo
  • Philippe Halimi
Head and Neck



To assess the performance of a simplified MRI protocol consisting of a contrast-enhanced three-dimensional MR angiography (CE-MRA) in association with a post-contrast T1-weighted sequence (T1WIV) for the detection of HNPGLs in SDHx mutation carriers.


This retrospective sub-study is based on the multicenter PGL.EVA cohort, which prospectively enrolled SDHx mutation carriers from 2005 to 2009; 157 index cases or relatives were included. CE-MRA and the T1WIV images were read solely with knowledge of the clinical data but blind to the diagnosis. Sensitivity, specificity and likelihood ratios for the simplified MRI protocol were compared to the full MRI protocol reading results and to the gold standard status obtained through the consensus of an expert committee.


The sensitivity and specificity of the readings of the simplified MRI protocol were, respectively, 88.7 % (95 % CI = 78.1–95.3) and 93.7 % (95 % CI = 86.8–97.7) versus 80.7 % (95 % CI = 68.6–89.6) and 94.7 % (95 % CI = 88.1–98.3) for the readings of the full MRI protocol.


The simplified post-contrast MRI with shorter duration (5 to 10 minutes) showed no performance difference compared to the lengthy standard full MRI and can be proposed for the detection of head and neck paragangliomas (HNPGLs) in SDHx mutation carriers.

Key Points

Rapid angio-MRI protocol and the usual lengthy protocol show equal diagnostic performance.

The CE-MRA is the key sequence for the detection of HNPGLs.

The T1WIV sequence assists in localizing HNPGLs.


Paraganglioma Head and neck Magnetic resonance angiography Screening SDH 



Head and neck paraganglioma


Contrast-enhanced three-dimensional MR angiography


Post-contrast T1-weighted sequence

Supplementary material

330_2015_4024_MOESM1_ESM.docx (57 kb)
ESM 1(DOCX 57 kb)


  1. 1.
    Mariman EC, van Beersum SE, Cremers CW et al (1993) Analysis of a second family with hereditary non-chromaffin paragangliomas locates the underlying gene at the proximal region of chromosome 11q. Hum Genet 91:357–361CrossRefPubMedGoogle Scholar
  2. 2.
    Lack EE, Cubilla AL, Woodruff JM, Farr HW (1977) Paragangliomas of the head and neck region. A clinical study of 69 patients. Cancer 39:397–409CrossRefPubMedGoogle Scholar
  3. 3.
    Castelblanco E, Gallel P, Ros S et al (2012) Thyroid paraganglioma. Report of 3 cases and description of an immunohistochemical profile useful in the differential diagnosis with medullary thyroid carcinoma, based on complementary DNA array results. Hum Pathol 43:1103–1112CrossRefPubMedGoogle Scholar
  4. 4.
    Alkadhi H, Schuknecht B, Stoeckli SJ, Valavanis A (2002) Evaluation of topography and vascularization of cervical paragangliomas by magnetic resonance imaging and color duplex sonography. Neuroradiology 44:83–90CrossRefPubMedGoogle Scholar
  5. 5.
    Olsen WL, Dillon WP, Kelly WM et al (1987) MR imaging of paragangliomas. AJR Am J Roentgenol 148:201–204CrossRefPubMedGoogle Scholar
  6. 6.
    van Gils AP, van den Berg R, Falke TH et al (1994) MR diagnosis of paraganglioma of the head and neck: value of contrast enhancement. AJR Am J Roentgenol 162:147–153CrossRefPubMedGoogle Scholar
  7. 7.
    Barber B, Ingram M, Khan S et al (2011) Clinicoradiological manifestations of paraganglioma syndromes associated with succinyl dehydrogenase enzyme mutation. Insights Imaging 2:431–438CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Gimenez-Roqueplo A-P, Caumont-Prim A, Houzard C et al (2013) Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J Clin Endocrinol Metab 98:E162–E173CrossRefPubMedGoogle Scholar
  9. 9.
    Baysal BE, Willett-Brozick JE, Lawrence EC et al (2002) Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet 39:178–183CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Boedeker CC, Neumann HPH, Maier W et al (2007) Malignant head and neck paragangliomas in SDHB mutation carriers. Off J Am Acad Otolaryngol-Head Neck Surg 137:126–129CrossRefGoogle Scholar
  11. 11.
    Drovdlic CM, Myers EN, Peters JA et al (2001) Proportion of heritable paraganglioma cases and associated clinical characteristics. Laryngoscope 111:1822–1827CrossRefPubMedGoogle Scholar
  12. 12.
    Badenhop RF, Jansen JC, Fagan PA et al (2004) The prevalence of SDHB, SDHC, and SDHD mutations in patients with head and neck paraganglioma and association of mutations with clinical features. J Med Genet 41:e99CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Favier J, Amar L, Gimenez-Roqueplo A-P (2014) Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol. doi:10.1038/nrendo.2014.188 PubMedGoogle Scholar
  14. 14.
    Favier J, Gimenez-Roqueplo A-P (2010) Pheochromocytomas: the (pseudo)-hypoxia hypothesis. Best Pract Res Clin Endocrinol Metab 24:957–968CrossRefPubMedGoogle Scholar
  15. 15.
    Burnichon N, Rohmer V, Amar L et al (2009) The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab 94:2817–2827CrossRefPubMedGoogle Scholar
  16. 16.
    Neumann HPH, Pawlu C, Peczkowska M et al (2004) Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA J Am Med Assoc 292:943–951CrossRefGoogle Scholar
  17. 17.
    Timmers HJLM, Kozupa A, Eisenhofer G et al (2007) Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 92:779–786CrossRefPubMedGoogle Scholar
  18. 18.
    Brewis C, Bottrill ID, Wharton SB, Moffat DA (2000) Metastases from glomus jugulare tumours. J Laryngol Otol 114:17–23PubMedGoogle Scholar
  19. 19.
    Lenders JWM, Duh Q-Y, Eisenhofer G et al (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:1915–1942CrossRefPubMedGoogle Scholar
  20. 20.
    Martin TPC, Irving RM, Maher ER (2007) The genetics of paragangliomas: a review. Clin Otolaryngol Off J ENT-UK Off J Neth Soc Oto-Rhino-Laryngol Cervico-Facial Surg 32:7–11CrossRefGoogle Scholar
  21. 21.
    Makeieff M, Raingeard I, Alric P et al (2008) Surgical management of carotid body tumors. Ann Surg Oncol 15:2180–2186CrossRefPubMedGoogle Scholar
  22. 22.
    Paris J, Facon F, Thomassin JM, Zanaret M (2006) Cervical paragangliomas: neurovascular surgical risk and therapeutic management. Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol - Head Neck Surg 263:860–865Google Scholar
  23. 23.
    Huy PTB, Kania R, Duet M et al (2009) Evolving concepts in the management of jugular paraganglioma: a comparison of radiotherapy and surgery in 88 cases. Skull Base Off J North Am Skull Base Soc Al 19:83–91Google Scholar
  24. 24.
    Dupin C, Lang P, Dessard-Diana B et al (2014) Treatment of head and neck paragangliomas with external beam radiation therapy. Int J Radiat Oncol Biol Phys 89:353–359CrossRefPubMedGoogle Scholar
  25. 25.
    Jansen JC, van den Berg R, Kuiper A et al (2000) Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal. Cancer 88:2811–2816CrossRefPubMedGoogle Scholar
  26. 26.
    Vogl T, Brüning R, Schedel H et al (1989) Paragangliomas of the jugular bulb and carotid body: MR imaging with short sequences and Gd-DTPA enhancement. AJR Am J Roentgenol 153:583–587CrossRefPubMedGoogle Scholar
  27. 27.
    Timmers HJLM, Chen CC, Carrasquillo JA et al (2012) Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst 104:700–708CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Neves F, Huwart L, Jourdan G et al (2008) Head and neck paragangliomas: value of contrast-enhanced 3D MR angiography. AJNR Am J Neuroradiol 29:883–889CrossRefPubMedGoogle Scholar
  29. 29.
    van den Berg R, Schepers A, de Bruïne FT et al (2004) The value of MR angiography techniques in the detection of head and neck paragangliomas. Eur J Radiol 52:240–245CrossRefPubMedGoogle Scholar
  30. 30.
    Jasperson KW, Kohlmann W, Gammon A et al (2014) Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families. Fam Cancer 13:257–265CrossRefPubMedGoogle Scholar
  31. 31.
    Hoegerle S, Ghanem N, Altehoefer C et al (2003) 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 30:689–694CrossRefPubMedGoogle Scholar
  32. 32.
    King KS, Chen CC, Alexopoulos DK et al (2011) Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab 96:2779–2785CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© European Society of Radiology 2015

Authors and Affiliations

  • Guillaume Gravel
    • 1
  • Patricia Niccoli
    • 2
  • Vincent Rohmer
    • 3
    • 4
  • Guy Moulin
    • 5
  • Françoise Borson-Chazot
    • 6
    • 7
    • 8
  • Pascal Rousset
    • 9
  • Anne Pasco-Papon
    • 10
  • Claude Marcus
    • 11
  • Frédérique Dubrulle
    • 12
  • Hervé Gouya
    • 13
  • François Bidault
    • 14
  • Benoit Dupas
    • 15
  • Jean Gabrillargues
    • 16
  • Aurore Caumont-Prim
    • 20
    • 21
  • Anne Hernigou
    • 1
  • Anne-Paule Gimenez-Roqueplo
    • 17
    • 18
    • 19
  • Philippe Halimi
    • 1
    • 19
  1. 1.Assistance Publique-Hôpitaux de Paris, Service de RadiologieHôpital Européen Georges PompidouParisFrance
  2. 2.Assistance Publique-Hôpitaux de Marseille, Service d’Endocrinologie, Diabète et Maladies MétaboliquesCentre Hospitalier Universitaire la TimoneMarseilleFrance
  3. 3.Service d’Endocrinologie, Diabétologie, NutritionCentre Hospitalier Universitaire d’AngersAngersFrance
  4. 4.LUNAM Université, INSERM, U1063AngersFrance
  5. 5.Assistance Publique-Hôpitaux de Marseille, Service de RadiologieCentre Hospitalier Universitaire la TimoneMarseilleFrance
  6. 6.Hospices civils de Lyon, Groupement Hospitalier EstFédération d’EndocrinologieLyonFrance
  7. 7.Faculté de Médecine Lyon-EstUniversité de LyonLyonFrance
  8. 8.INSERM UMR1052, UMR CNRS 5286Cancer Research Center of LyonLyonFrance
  9. 9.Groupement Hospitalier Est, Service de RadiologieHospices civils de LyonLyonFrance
  10. 10.Service de RadiologieCentre Hospitalier Universitaire d’AngersAngersFrance
  11. 11.Service de RadiologieCentre Hospitalo-Universitaire de ReimsReimsFrance
  12. 12.Service de RadiologieCentre Hospitalo-Universitaire de LilleLilleFrance
  13. 13.Assistance Publique-Hôpitaux de Paris, Service de RadiologieHôpital CochinParisFrance
  14. 14.Service de RadiologieInstitut Gustave RoussyVillejuifFrance
  15. 15.Service de RadiologieCentre Hospitalo-Universitaire de NantesNantesFrance
  16. 16.Service de NeuroradiologieCentre Hospitalo-Universitaire de Clermont-FerrandClermont FerrandFrance
  17. 17.Assistance Publique-Hôpitaux de Paris, Service de GénétiqueHôpital Européen Georges PompidouParisFrance
  18. 18.INSERM, UMR970Paris Cardiovascular Research CenterParisFrance
  19. 19.Sorbonne Paris Cité, Faculté de MédecineUniversité Paris DescartesParisFrance
  20. 20.Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges PompidouUnité d’Épidémiologie et de Recherche CliniqueParisFrance
  21. 21.INSERMCentre d’investigation Épidémiologique 4ParisFrance

Personalised recommendations